Hoffmann-La Roche: Phase 3 study closed enrollment, 342 enrolled (Hepatocellular Carcinoma)
Hoffmann-La Roche: Phase 3 study closed enrollment, 342 enrolled (Hepatocellular Carcinoma). Its enrollment of 342 is above the median of 80 (85th percentile). Dated 9 days ago, it is in the active follow-up window. Score 100/100. As of 2026-11-04, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 342 · 85th percentile of 8,879 ClinicalTrialStartPulse records · 4.3x the median
Free preview: all 15 published fields of this record are shown below. Locked: 499 related ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma |
| NCT ID | NCT04712643 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | Hepatocellular Carcinoma |
| Intervention types | drug, device |
| Target enrollment | 342 |
| Site countries | China, Japan |
| Posted | 2021-01-15 |
| Planned start | 2021-03-12 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-26 |
| Last update posted | 2026-10-26 |
| enrollment percentile | 85th of 8,879 (median 80, 4.3x median) |
| Peer records CSV (500 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch Hoffmann-La Roche
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Unlock Hoffmann-La Roche + 500 peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-10-26
- Data refreshed: 2026-11-04
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (NONUS first): University of Oxford · DejthidaNathaphong · Eye & ENT Hospital of Fudan University · Shanghai First Maternal and Infant Health Hospital affiliate · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Wed, 04 Nov 2026 06:04:38 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: Hoffmann-La Roche and 6,603 NONUS peers
- NONUS ClinicalTrialStartPulse records like this one: 6,603
- Hoffmann-La Roche's enrollment: 85th percentile of 8,879 records
- Timing: Medium: dated in the last 30 days
- Estimated pipeline if you contact every NONUS peer: $1,320,600 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
100 / 100 Score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.
- 342 participants planned.
What is the ClinicalTrialStartPulse record for Hoffmann-La Roche?
Hoffmann-La Roche's Phase 3 study (NCT04712643) in Hepatocellular Carcinoma, first posted 2021-01-15: enrollment closed (active, not recruiting) (2026-10-26), in an update posted 2026-10-26.
How does Hoffmann-La Roche compare to other ClinicalTrialStartPulse records?
Its enrollment of 342 sits in the upper half (85th percentile) of 8,879 records; the median is 80. It is fresh: dated 9 days ago, inside the window where early outreach matters most. Its Score of 100/100 puts it among the stronger signals in this feed.
Hoffmann-La Roche vs. top 3 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| Hoffmann-La Roche | NONUS | 342 | 85th | 2026-10-26 |
| Janssen-Cilag Ltd. | US | 288 | 82nd | 2026-11-03 |
| Genmab | US | 191 | 75th | 2026-11-03 |
| AstraZeneca | US | 181 | 74th | 2026-11-03 |
Related records
ClinicalTrialStartPulse: Phase 3 ClinicalTrialStartPulse: Outside the US only
How to monitor Hoffmann-La Roche and peer phase 3 records
Get new ClinicalTrialStartPulse records like Hoffmann-La Roche by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.